BIOGEN INC. DL -,0005 | 221.4000 / -0.27% |
Date/Time | 01/21 / 16:35 |
Chg. / Chg.(%) | -0.6000 / -0.27% |
Bid | - |
Ask | - |
Open | 222.1000 |
Previous Close | 222.0000 |
High | 224.4000 |
Low | 221.4000 |
Volume [EUR] | 122,299.9000 |
Volume [Units] | 547 |
Price fixings | 11 |
ISIN | US09062X1037 |
Security | IDP |
Exchange | Frankfurt |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 270.1200 | ![]() |
806,526 |
IEX | 270.10 | ![]() |
51,904 |
Cboe US | 270.13 | ![]() |
24,867 |
London Inter.. | 268.49 | ![]() |
2,363 |
TradeGate | 221.350 | ![]() |
1,108 |
Xetra | 221.85 | ![]() |
604 |
Frankfurt | 221.4000 | ![]() |
547 |
Stuttgart | 222.050 | ![]() |
147 |
Vienna Globa.. | 221.65 | ![]() |
136 |
gettex | 221.450 | ![]() |
117 |
München | 222.80 | ![]() |
0 |
Hamburg | 222.00 | ![]() |
0 |
Düsseldorf | 220.75 | ![]() |
0 |
Berlin | 221.15 | ![]() |
0 |
Hannover | 222.00 | ![]() |
0 |
Lang & Schwa.. | 220.550 | ![]() |
|
Mexico | 5,408.00 | ![]() |
11 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire